PubRank
Search
About
Gamal Akabani
Author PubWeight™ 19.06
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
J Neurooncol
2003
1.63
2
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.
J Nucl Med
2010
1.61
3
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
Neuro Oncol
2008
1.59
4
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
J Nucl Med
2007
1.57
5
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
J Clin Oncol
2002
1.32
6
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
J Clin Oncol
2006
1.12
7
Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.
Neurosurg Focus
2006
1.06
8
An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
J Gene Med
2004
1.00
9
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Neuro Oncol
2008
0.99
10
Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT.
Radiology
2007
0.91
11
Radioimmunotherapy for Non-Hodgkin's Lymphoma.
Clin Med Res
2005
0.91
12
In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.
J Nucl Med
2003
0.85
13
The role of cAMP-dependent signaling in receptor-recognized forms of alpha 2-macroglobulin-induced cellular proliferation.
J Biol Chem
2002
0.83
14
Comparative dosimetry of BEIR VI revisited.
Radiat Prot Dosimetry
2004
0.83
15
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
J Nucl Med
2006
0.82
16
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.
Blood
2004
0.82
17
Feasibility of whole-body functional mouse imaging using helical pinhole SPECT.
Mol Imaging Biol
2009
0.80
18
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
Nucl Med Biol
2007
0.78
19
Preliminary production of 211At at the Texas A&M University Cyclotron Institute.
Health Phys
2014
0.75
20
Radiological safety concerns for the accelerator production of diagnostic and therapeutic radionuclides in a university setting.
Health Phys
2012
0.75